Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics
- 15 June 2021
- journal article
- review article
- Published by Taylor & Francis Ltd in Expert Opinion on Biological Therapy
- Vol. 21 (7), 945-962
- https://doi.org/10.1080/14712598.2021.1936494
Abstract
: Advanced breast cancer (aBC) remains incurable and the quest for more effective systemic anticancer agents continues. Promising results have led to the FDA approval of three antibody-drug conjugates (ADCs) and two immune checkpoint inhibitors (ICIs) to date for patients with aBC. : With the anticipated emergence of newer ADCs and ICIs for patients with several subtypes of breast cancer, and given their potential synergy, their use in combination is of clinical interest. In this article, we review the use of ADCs and ICIs in patients with breast cancer, assess the scientific rationale for their combination, and provide an overview of ongoing trials and some early efficacy and safety results of such dual therapy. : Improvement in the medicinal chemistry of next-generation ADCs, their rational combination with ICIs and other agents, and the development of multiparametric immune biomarkers could help to significantly improve the outlook for patients with refractory aBC.Keywords
Funding Information
- funded
This publication has 171 references indexed in Scilit:
- Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody–Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other CancersBioconjugate Chemistry, 2015
- Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potentialTherapeutic Advances in Medical Oncology, 2014
- The immune system and response to HER2-targeted treatment in breast cancerThe Lancet Oncology, 2014
- Oncology Meets Immunology: The Cancer-Immunity CycleImmunity, 2013
- Trastuzumab Emtansine for HER2-Positive Advanced Breast CancerThe New England Journal of Medicine, 2012
- Upregulation of Trop-2 quantitatively stimulates human cancer growthOncogene, 2012
- Anti–ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti–PD-1 or anti-CD137 mAb therapyProceedings of the National Academy of Sciences of the United States of America, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Prevention and management of major side effects of targeted agents in breast cancerCritical Reviews in Oncology/Hematology, 2010
- The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive ImmunityCancer Cell, 2010